Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study

類似資料

• Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients
  著者:: Mukai, Hirofumi, 等
  出版事項: (2018)
• Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA‐2 Trial
  著者:: Diéras, Véronique, 等
  出版事項: (2019)
• Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3
  著者:: Masuda, Norikazu, 等
  出版事項: (2020)
• Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial
  著者:: Rugo, H S, 等
  出版事項: (2018)
• PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients
  著者:: Iwata, Hiroji, 等
  出版事項: (2017)